DocMorris (DOCM.SW) Stock Price

DocMorris Price

SIX·CLOSED
10.16CHF+0.18 (+1.84 %)
Market closed

Revenue has compounded at 5.7% per year over the past 12 years to 1.02 B CHF. Earnings per share have grown at 5.6% per year over the last 11 years. DocMorris's net margin stands at -9.6%, broadly stable from -9.2% several years earlier. Analysts set a median price target of 8.26 CHF, implying 18.7% below the current price. Of 13 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 155% above its 52-week low.

DocMorris stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of DocMorris over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how DocMorris stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing DocMorris's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

DocMorris Stock Price History
DateDocMorris Price
7/14/202610.16 CHF
7/13/20269.98 CHF
7/10/20268.58 CHF
7/9/20268.69 CHF
7/8/20269.00 CHF
7/7/20269.18 CHF
7/6/20269.09 CHF
7/3/20269.24 CHF
7/2/20269.10 CHF
7/1/20269.13 CHF
6/30/20268.76 CHF
6/29/20268.79 CHF
6/26/20268.30 CHF
6/25/20268.15 CHF
6/24/20267.91 CHF
6/23/20267.91 CHF
6/22/20268.03 CHF
6/19/20268.16 CHF
6/18/20268.49 CHF
6/17/20268.52 CHF
6/16/20268.00 CHF
6/15/20267.93 CHF
6/12/20267.86 CHF
6/11/20267.70 CHF
6/10/20267.21 CHF
6/9/20267.26 CHF
6/8/20267.35 CHF
6/5/20267.45 CHF
6/4/20267.33 CHF
6/3/20267.47 CHF
6/2/20267.18 CHF
6/1/20267.17 CHF
5/29/20267.03 CHF
5/28/20266.94 CHF
5/27/20266.73 CHF
5/26/20266.70 CHF
5/22/20266.64 CHF
5/21/20266.62 CHF
5/20/20266.91 CHF
5/19/20266.92 CHF
5/18/20267.11 CHF
5/15/20267.18 CHF
5/13/20267.28 CHF
5/12/20266.98 CHF
5/11/20267.09 CHF
5/8/20267.03 CHF
5/7/20267.37 CHF
5/6/20267.43 CHF
5/5/20267.24 CHF
5/4/20267.05 CHF
4/30/20267.11 CHF
4/29/20267.19 CHF
4/28/20267.05 CHF
4/27/20267.00 CHF
4/24/20267.09 CHF
4/23/20266.95 CHF
4/22/20267.00 CHF
4/21/20267.26 CHF
4/20/20267.26 CHF
4/17/20266.61 CHF
4/16/20266.35 CHF
4/15/20265.74 CHF
4/14/20265.75 CHF
4/13/20265.63 CHF
4/10/20265.49 CHF
4/9/20265.54 CHF
4/8/20265.32 CHF
4/7/20264.82 CHF
4/2/20265.01 CHF
4/1/20264.97 CHF
3/31/20264.81 CHF
3/30/20264.27 CHF
3/27/20264.21 CHF
3/26/20264.23 CHF
3/25/20264.33 CHF
3/24/20263.98 CHF
3/23/20264.02 CHF
3/20/20264.09 CHF
3/19/20264.01 CHF
3/18/20264.12 CHF
3/17/20264.29 CHF
3/16/20264.01 CHF
3/13/20264.49 CHF
3/12/20264.74 CHF
3/11/20264.80 CHF
3/10/20264.80 CHF
3/9/20264.80 CHF
3/6/20264.82 CHF
3/5/20264.90 CHF
3/4/20264.95 CHF
3/3/20265.07 CHF
3/2/20265.24 CHF
2/27/20265.16 CHF
2/26/20265.13 CHF
2/25/20265.14 CHF
2/24/20265.07 CHF
2/23/20265.25 CHF
2/20/20265.39 CHF
2/19/20265.39 CHF
2/18/20265.55 CHF
2/17/20265.58 CHF
2/16/20265.70 CHF
2/13/20265.64 CHF
2/12/20265.70 CHF
2/11/20265.66 CHF
2/10/20265.91 CHF
2/9/20265.62 CHF
2/6/20265.65 CHF
2/5/20265.84 CHF
2/4/20265.84 CHF
2/3/20265.68 CHF
2/2/20265.70 CHF
1/30/20265.60 CHF
1/29/20265.61 CHF
1/28/20265.97 CHF
1/27/20265.53 CHF
1/26/20265.43 CHF
1/23/20265.74 CHF
1/22/20266.39 CHF
1/21/20265.76 CHF
1/20/20265.90 CHF
1/19/20266.45 CHF
1/16/20266.57 CHF
1/15/20266.03 CHF
1/14/20266.03 CHF
1/13/20266.02 CHF
1/12/20266.01 CHF
1/9/20266.13 CHF
1/8/20266.23 CHF
1/7/20266.50 CHF
1/6/20266.59 CHF
1/5/20265.99 CHF
12/30/20255.95 CHF
12/29/20255.84 CHF
12/23/20255.63 CHF
12/22/20255.64 CHF
12/19/20255.51 CHF
12/18/20255.38 CHF
12/17/20255.51 CHF
12/16/20255.55 CHF
12/15/20255.57 CHF
12/12/20255.90 CHF
12/11/20255.80 CHF
12/10/20255.57 CHF
12/9/20255.57 CHF
12/8/20255.32 CHF
12/5/20255.36 CHF
12/4/20255.45 CHF
12/3/20255.39 CHF
12/2/20255.64 CHF
12/1/20255.55 CHF
11/28/20255.49 CHF
11/27/20255.39 CHF
11/26/20255.14 CHF
11/25/20255.18 CHF
11/24/20254.94 CHF
11/21/20254.82 CHF
11/20/20254.89 CHF
11/19/20255.05 CHF
11/18/20255.07 CHF
11/17/20255.07 CHF
11/14/20255.16 CHF
11/13/20255.34 CHF
11/12/20255.42 CHF
11/11/20255.34 CHF
11/10/20255.18 CHF
11/7/20255.06 CHF
11/6/20254.99 CHF
11/5/20255.03 CHF
11/4/20255.15 CHF
11/3/20255.28 CHF
10/31/20255.52 CHF
10/30/20255.53 CHF
10/29/20255.57 CHF
10/28/20255.60 CHF
10/27/20255.45 CHF
10/24/20255.45 CHF
10/23/20255.41 CHF
10/22/20255.37 CHF
10/21/20255.92 CHF
10/20/20256.17 CHF
10/17/20256.24 CHF
10/16/20256.62 CHF
10/15/20256.16 CHF
10/14/20256.14 CHF
10/13/20256.11 CHF
10/10/20256.27 CHF
10/9/20256.34 CHF
10/8/20256.22 CHF
10/7/20256.38 CHF
10/6/20256.49 CHF
10/3/20256.18 CHF
10/2/20255.93 CHF
10/1/20255.80 CHF
9/30/20255.88 CHF
9/29/20255.78 CHF
9/26/20255.68 CHF
9/25/20255.88 CHF
9/24/20255.95 CHF
9/23/20256.12 CHF
9/22/20256.28 CHF
9/19/20256.28 CHF
9/18/20256.58 CHF
9/17/20256.30 CHF
9/16/20256.13 CHF
9/15/20256.29 CHF
9/12/20256.26 CHF
9/11/20256.08 CHF
9/10/20256.09 CHF
9/9/20256.24 CHF
9/8/20256.20 CHF
9/5/20256.34 CHF
9/4/20256.47 CHF
9/3/20256.32 CHF
9/2/20256.49 CHF
9/1/20256.66 CHF
8/29/20256.60 CHF
8/28/20256.61 CHF
8/27/20257.05 CHF
8/26/20257.11 CHF
8/25/20256.92 CHF
8/22/20256.97 CHF
8/21/20256.70 CHF
8/20/20256.93 CHF
8/19/20256.78 CHF
8/18/20257.66 CHF
8/15/20257.63 CHF
8/14/20257.99 CHF
8/13/20258.00 CHF
8/12/20257.94 CHF
8/11/20258.00 CHF
8/8/20258.08 CHF
8/7/20258.53 CHF
8/6/20258.39 CHF
8/5/20258.55 CHF
8/4/20258.09 CHF
7/31/20257.70 CHF
7/30/20257.76 CHF
7/29/20257.82 CHF
7/28/20258.16 CHF
7/25/20258.29 CHF
7/24/20257.88 CHF
7/23/20257.61 CHF
7/22/20257.89 CHF
7/21/20257.93 CHF
7/18/20258.07 CHF
7/17/20258.41 CHF
Access this data via the Eulerpool API
Get Free API Key

DocMorris Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
1.61 B CHF
-133.90 M CHF
-171.10 M CHF
Jan 1, 2023
969.46 M CHF
-81.81 M CHF
82.28 M CHF
Jan 1, 2024
1.02 B CHF
-103.09 M CHF
-97.25 M CHF
Jan 1, 2025 (e)
1.15 B CHF
-97.36 M CHF
-121.88 M CHF
Jan 1, 2026 (e)
1.29 B CHF
-69.42 M CHF
-86.03 M CHF
Jan 1, 2027 (e)
1.47 B CHF
-37.14 M CHF
-49.10 M CHF
Jan 1, 2028 (e)
1.63 B CHF
-3.93 M CHF
-20.01 M CHF
Jan 1, 2029 (e)
1.78 B CHF
12.99 M CHF
3.36 M CHF

DocMorris Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 16, 2026, 7:34 PM
 
REVENUEB CHF
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CHF
NET INCOMEM CHF
NET INCOME GROWTH%
SHARESM
2016201720182019202020212022202320242025e2026e2027e2028e2029e2030e2031e
0.880.981.211.361.481.731.610.971.021.151.291.471.631.782.502.66
5.4011.7222.9112.268.9316.94-6.84-39.744.9512.7812.1214.0011.059.5840.256.12
15.0214.9715.8215.3516.8715.4115.2420.9521.2421.2421.2421.2421.2421.2421.2421.24
132.00147.00191.00208.00249.00266.00245.00203.00216.00243.61273.13311.36345.77378.90531.40563.89
-12.00-36.00-39.00-52.00-135.00-225.00-171.0082.00-97.00-121.00-86.00-49.00-20.003.00––
-500.00200.008.3333.33159.6266.67-24.00-147.95-218.2924.74-28.93-43.02-59.18-115.00––
3.705.506.308.709.109.6010.8023.7123.9523.9523.9523.9523.9523.9523.9523.95
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales DocMorris generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue DocMorris retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare DocMorris's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares DocMorris has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against DocMorris's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

DocMorris stock margins

The DocMorris margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DocMorris. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DocMorris.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
16.86 %
-7.40 %
-9.19 %
Jan 1, 2021
15.41 %
-10.99 %
-13.07 %
Jan 1, 2022
15.27 %
-8.33 %
-10.64 %
Jan 1, 2023
20.98 %
-8.44 %
8.49 %
Jan 1, 2024
21.29 %
-10.14 %
-9.56 %
Jan 1, 2025 (e)
21.29 %
-8.49 %
-10.63 %
Jan 1, 2026 (e)
21.29 %
-5.40 %
-6.69 %
Jan 1, 2027 (e)
21.29 %
-2.53 %
-3.35 %

DocMorris Stock Revenue, EBIT, Earnings per Share

The DocMorris earnings per share therefore indicates how much revenue DocMorris has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
162.30 CHF
-12.01 CHF
-14.91 CHF
Jan 1, 2021
179.84 CHF
-19.77 CHF
-23.51 CHF
Jan 1, 2022
148.91 CHF
-12.40 CHF
-15.84 CHF
Jan 1, 2023
40.89 CHF
-3.45 CHF
3.47 CHF
Jan 1, 2024
42.47 CHF
-4.30 CHF
-4.06 CHF
Jan 1, 2025 (e)
22.22 CHF
-4.07 CHF
-2.36 CHF
Jan 1, 2026 (e)
24.91 CHF
-2.90 CHF
-1.67 CHF
Jan 1, 2027 (e)
28.40 CHF
-1.55 CHF
-0.95 CHF

DocMorris business model & stock analysis

The Zur Rose Group AG is a Swiss company that specializes in online trading of medications and health products. The company was founded in 1993 in Steckborn and initially focused on the mail order of homeopathic medicines. In 1997, the online shop www.zurrose.de was opened and the company began to expand its distribution to non-homeopathic medicines. The business model of the Zur Rose Group AG is based on a three-pillar model, encompassing e-commerce, wholesale, and healthcare. In the e-commerce sector, the company operates online pharmacies in various countries including Germany, France, Austria, the Netherlands, and Switzerland. In the wholesale sector, the company supplies pharmacies and hospitals with medicines and medical products. In the healthcare sector, the company offers various services in healthcare, from the production of medicines to the processing of prescriptions. The Zur Rose Group AG offers a wide range of products and services including prescription and over-the-counter medications, natural remedies, cosmetic products, dietary supplements, and medical devices. The company aims to provide its customers with a comprehensive selection of high-quality products and works closely with its suppliers to ensure that all products meet the highest quality standards. In the e-commerce sector, the company operates various online pharmacies, including Zur Rose Apotheke in Germany, Zur Rose Apotheke in Austria, and Doctipharma in France. These online pharmacies offer a wide range of medications and health products that can be ordered online and conveniently delivered to customers' homes. The online pharmacies are open 24/7, allowing customers to quickly and easily order their needed medications. In the wholesale sector, the company offers a wide range of pharmaceutical products and medical devices to pharmacies and hospitals. The company works closely with its suppliers to ensure that all products meet the highest quality standards. Additionally, the company also provides a fast and reliable delivery service to ensure that its customers are always provided with the needed medications and medical products. In the healthcare sector, the company offers various services in healthcare, including digitalization solutions for pharmacies, manufacturing of medications, and processing of prescriptions. The company works closely with its customers to offer tailored solutions that meet their individual requirements. Over the years, the Zur Rose Group AG has become a leading provider in the online trading of medications and health products. The company has distinguished itself through its wide product range, fast and reliable delivery service, and excellent customer service. Additionally, the company has also invested in the development of new technologies to ensure that it can always offer its customers the best products and services. Overall, the Zur Rose Group AG is an innovative company built on a long history in healthcare. The company strives to offer its customers a wide range of high-quality products and services and has established itself as a leading provider in the online trading of medications and health products.

DocMorris SWOT Analysis

Strengths

Zur Rose Group AG has a strong brand presence and recognition in the pharmaceutical industry.

The company has a wide range of products and services, providing convenience and accessibility to customers.

Zur Rose Group AG benefits from economies of scale due to its large customer base and extensive distribution network.

Weaknesses

Zur Rose Group AG faces intense competition from both traditional brick-and-mortar pharmacies and other online pharmacies.

The company's profitability is dependent on reimbursement rates from healthcare insurance providers.

Zur Rose Group AG may also face challenges in gaining customer trust and loyalty due to the sensitive nature of the pharmaceutical industry.

Opportunities

The growing trend towards e-commerce and digitalization in the healthcare sector provides an opportunity for Zur Rose Group AG to expand its online presence.

The increasing demand for personalized healthcare services opens avenues for the company to offer tailored product recommendations and improved customer experience.

Zur Rose Group AG can explore partnerships and collaborations with healthcare providers and insurers to enhance its service offerings.

Threats

Regulatory changes and compliance requirements pose a significant threat to Zur Rose Group AG's operations and profitability.

The emergence of counterfeit drugs in the online market can tarnish the company's reputation and erode customer trust.

Changes in consumer behavior and preferences can impact the demand for online pharmaceutical services.

DocMorris Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

DocMorris historical P/E ratio, EBIT multiple, and P/S ratio

DocMorris annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

DocMorris shares outstanding

The number of shares of DocMorris was 23.95 M in 2025. This indicates how many shares DocMorris is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
9.10 M Stocks
Jan 1, 2021
9.60 M Stocks
Jan 1, 2022
10.80 M Stocks
Jan 1, 2023
23.71 M Stocks
Jan 1, 2024
23.95 M Stocks
Jan 1, 2025 (e)
23.95 M Stocks
Jan 1, 2026 (e)
23.95 M Stocks
Jan 1, 2027 (e)
23.95 M Stocks

Current DocMorris forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy53.85 % (7)
Hold38.46 % (5)
Sell7.69 % (1)
12M Price Target
8.26
Last Price
10.43
Currency
CHF
12M Return Potential
-20.79 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the DocMorris stock

61/100
44
Environment
50
Social
89
Governance
E

Environment

20
Scope 1 - Direct Emissions260
Scope 2 - Indirect emissions from purchased energy2,692
Scope 3 - Indirect emissions within the value chain4,748
Total CO₂ emissions2,952
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees49.7
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

DocMorris shareholder structure

% Name
11.18017%
Pelion SA
Pelion SA
9.71315%
UBS Asset Management (Switzerland)
UBS Asset Management (Switzerland)
4.88742%
Zürcher Kantonalbank (Asset Management)
Zürcher Kantonalbank (Asset Management)
3.20515%
Sterling Strategic Value Fund S.A., SICAV-RAIF
Sterling Strategic Value Fund S.A., SICAV-RAIF
3.01010%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
1.81633%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG
...

DocMorris Executives and Management Board

WH

Mr. Walter Hess

(60)

Chief Executive Officer, Member of the Executive Board, Head Germany

Compensation1.82 M CHF
WO

Mr. Walter Oberhaensli

(67)

Non-Executive Chairman of the Board · since 1996

Compensation379,000.00 CHF
PF

Prof. Stefan Feuerstein

(70)

Non-Executive Independent Vice Chairman of the Board of Directors

Compensation207,000.00 CHF
CM

Dr. Christian Mielsch

(62)

Non-Executive Independent Member of the Board of Directors

Compensation190,000.00 CHF
PB

Prof. Dr. Andrea Belliger

(55)

Non-Executive Independent Member of the Board of Directors

Compensation166,000.00 CHF

Frequently asked questions about DocMorris

The business model of Zur Rose Group AG is focused on providing pharmaceutical and healthcare services. As a leading online pharmacy in Europe, Zur Rose offers a wide range of products and services. The company operates in two segments, namely the Pharmacy and the Services segments. Through its online platform, Zur Rose enables customers to order prescription and over-the-counter drugs, as well as healthcare products, from the comfort of their homes. Additionally, Zur Rose provides services to healthcare professionals, such as logistics and wholesale services. Overall, Zur Rose's business model aims to enhance the accessibility and convenience of pharmaceutical and healthcare products for its customers.

All fundamentals and in-depth analysis of DocMorris

Our stock analysis for DocMorris stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DocMorris. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

DocMorris Stock
DocMorris Revenue→
DocMorris Stock
DocMorris Net Income→
DocMorris Stock
DocMorris P/E→
DocMorris Stock
DocMorris P/S→
DocMorris Stock
DocMorris EBIT→
DocMorris Stock
DocMorris Dividend→
DocMorris Stock
DocMorris Directors Dealings→
DocMorris Stock
DocMorris Stocks→
DocMorris Stock
DocMorris Market capitalization→
DocMorris Stock
DocMorris Debt→
DocMorris Stock
DocMorris Liabilities→
DocMorris Stock
DocMorris Equity→
DocMorris Stock
DocMorris AAQS→
DocMorris Stock
DocMorris Employees→
DocMorris Stock
DocMorris ROE→
DocMorris Stock
DocMorris ROA→
DocMorris Stock
DocMorris ROCE→
DocMorris Stock
DocMorris News→
DocMorris Stock
DocMorris Analyst Price Targets→

Non-cyclical consumption Stocks

DOD Biotech PCLDo Day Dream PCLDodla DairyDND TechnologiesDoleDNA BrandsDollex AgrotechDkhoun National Trading Company SCJSCDonegal Investment GroupDistribuidora Internacional de AlimentacionDong Suh CompaniesDis-Chem PharmaciesAll Stocks A–Z →